Julia Krämer

Dr. Julia Krämer


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
RWRebecca Wicklein
Rebecca Wicklein
CYCharmaine Yam
Charmaine Yam
CNChristina Noll
Christina Noll
LALilian Aly
Lilian Aly
NBNicolas Banze
Nicolas Banze
OCon behalf of IMSVISUAL Consortium
on behalf of IMSVISUAL Consortium
Background and Objectives Optical coherence tomography angiography (OCTA) is a noninvasive high-resolution imaging technique for assessing the retinal vasculature and is increasingly used in various ophthalmologic, neuro-ophthalmologic, and neurologic diseases. To date, there are no validated consensus criteria for quality control (QC) of OCTA. Our study aimed to develop criteria for OCTA quality assessment. Methods To establish criteria through (1) extensive literature review on OCTA artifacts and image quality to generate standardized and easy-to-apply OCTA QC criteria, (2) application of OCTA QC criteria to evaluate interrater agreement, (3) identification of reasons for interrater disagreement, revision of OCTA QC criteria, development of OCTA QC scoring guide and training set, and (4) validation of QC criteria in an international, interdisciplinary multicenter study. Results We identified 7 major aspects that affect OCTA quality: (O) obvious problems, (S) signal strength, (C) centration, (A) algorithm failure, (R) retinal pathology, (M) motion artifacts, and (P) projection artifacts. Seven independent raters applied the OSCAR-MP criteria to a set of 40 OCTA scans from people with MS, Sjogren syndrome, and uveitis and healthy individuals. The interrater kappa was substantial (κ 0.67). Projection artifacts were the main reason for interrater disagreement. Because artifacts can affect only parts of OCTA images, we agreed that prior definition of a specific region of interest (ROI) is crucial for subsequent OCTA quality assessment. To enhance artifact recognition and interrater agreement on reduced image quality, we designed a scoring guide and OCTA training set. Using these educational tools, 23 raters from 14 different centers reached an almost perfect agreement (κ 0.92) for the rejection of poor-quality OCTA images using the OSCAR-MP criteria. Discussion We propose a 3-step approach for standardized quality control: (1) To define a specific ROI, (2) to assess the occurrence of OCTA artifacts according to the OSCAR-MP criteria, and (3) to evaluate OCTA quality based on the occurrence of different artifacts within the ROI. OSCAR-MP OCTA QC criteria achieved high interrater agreement in an international multicenter study and is a promising QC protocol for application in the context of future clinical trials and studies.

Verified
Journal Article
Open access
PDF file
JKJulia Krämer
Julia Krämer
Sven G. MeuthSven G. Meuth
Sven G. Meuth
JTJan-Gerd Tenberge
Jan-Gerd Tenberge
PSPatrick Schiffler
Patrick Schiffler
HWHeinz Wiendl
Heinz Wiendl
MDMichael Deppe
Michael Deppe
Putamen atrophy and its long-term progress during disease course were recently shown in patients with multiple sclerosis (MS). Here we investigated retrospectively the time point of atrophy onset in patients with relapsing-remitting MS (RRMS). 68 patients with RRMS and 26 healthy controls (HC) were admitted to 3T MRI in a cross-sectional study. We quantitatively analyzed the putamen volume of individual patients in relation to disease duration by correcting for age and intracranial volume (ICV). Patient’s relative putamen volume (RPV), expressed in percent of ICV, was significantly reduced compared to HC. Based on the correlation between RPV and age, we computed the age-corrected RPV deviation (ΔRPV) from HC. Patients showed significantly negative ΔRPV. Interestingly, the age-corrected ΔRPV depended logarithmically on disease duration: Directly after first symptom manifestation, patients already showed a reduced RPV followed by a further degressive volumetric decline. This means that atrophy progression was stronger in the first than in later years of disease. Putamen atrophy starts directly after initial symptom manifestation or even years before, and progresses in a degressive manner. Due to its important role in neurological functions, early detection of putamen atrophy seems necessary. High-resolution structural MRI allows monitoring of disease course.

8 May 2019 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
LLLisa Langenbruch
Lisa Langenbruch
JKJulia Krämer
Julia Krämer
SGSati Güler
Sati Güler
GMGabriel Möddel
Gabriel Möddel
SGSophia Geßner
Sophia Geßner
SKStjepana Kovac
Stjepana Kovac

19 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JKJulia Krämer
Julia Krämer
CBCarolin Balloff
Carolin Balloff
MWMargit Weise
Margit Weise
VKValeria Koska
Valeria Koska
YUYannik Uthmeier
Yannik Uthmeier
PAPhilipp Albrecht
Philipp Albrecht
Retinal optical coherence tomography has been identified as biomarker for disease progression in relapsing-remitting multiple sclerosis (RRMS), while the dynamics of retinal atrophy in progressive MS are less clear. We investigated retinal layer thickness changes in RRMS, primary and secondary progressive MS (PPMS, SPMS), and their prognostic value for disease activity. Here, we analyzed 2651 OCT measurements of 195 RRMS, 87 SPMS, 125 PPMS patients, and 98 controls from five German MS centers after quality control. Peripapillary and macular retinal nerve fiber layer (pRNFL, mRNFL) thickness predicted future relapses in all MS and RRMS patients while mRNFL and ganglion cell-inner plexiform layer (GCIPL) thickness predicted future MRI activity in RRMS (mRNFL, GCIPL) and PPMS (GCIPL). mRNFL thickness predicted future disability progression in PPMS. However, thickness change rates were subject to considerable amounts of measurement variability. In conclusion, retinal degeneration, most pronounced of pRNFL and GCIPL, occurs in all subtypes. Using the current state of technology, longitudinal assessments of retinal thickness may not be suitable on a single patient level.

1 November 2019 in Progress in Neurobiology
Verified
Journal Article
Closed access
JKJulia Krämer
Julia Krämer
WBWolfgang Brück
Wolfgang Brück
FZFrauke Zipp
Frauke Zipp
MCManuela Cerina
Manuela Cerina
SGSergiu Groppa
Sergiu Groppa
Sven G. MeuthSven G. Meuth
Sven G. Meuth

1 May 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
Christoph HeesenChristoph Heesen
Christoph Heesen
IKIngo Kleiter
Ingo Kleiter
SMSven G. Meuth
Sven G. Meuth
JKJulia Krämer
Julia Krämer
JKJürgen Kasper
Jürgen Kasper
WGWolfgang Gaissmaier
Wolfgang Gaissmaier